ESMO 2016: Niraparib significantly improves outcome of ovarian cancer patients in landmark trial
The PARP inhibitor niraparib significantly improves the outcome of platinum-sensitive recurrent ovarian cancer, according to…
Browsing: platinum-sensitive recurrent ovarian cancer